Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
67.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.00 (3.03%)
Market Cap: £81.62m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

PCA Dealing

12 Feb 2026 17:40

RNS Number : 8457S
Venture Life Group PLC
12 February 2026
 

12 February 2026

 

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Group")

PCA Dealing

 

Venture Life Group PLC (AIM: VLG), a recognised leader in proactive healthy, product innovation, development, and commercialisation within the global consumer healthcare sector, announces that it was notified on 11 February 2026 that Lewis Arthur, a PCA of Sarah Arthur, Interim Commercial Director of the Company, purchased 2,959 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") at a price of 67.38p per Ordinary Share on 29 January 2026 (the "Purchase").

Following the Purchase, Sarah Arthur's beneficial interest in the Company, including those held by her PCA, is 2,959 Ordinary Shares, representing 0.002 per cent. of the issued share capital of the Company.

 

For further information, please contact:

Venture Life Group PLC +44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500 

Stephen Keys/George Lawson (Corporate Finance)

Michael Johnson (Sales) 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 The notification below, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018), provide further detail on the share dealings.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Lewis Arthur

2

 

Reason for the notification

 

a)

 

Position/status

 

PCA of Sarah Arthur, Interim Commercial Director

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Venture Life Group plc

b)

 

LEI

 

213800S8CZUPLAB2KC70

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 

Identification code

 

Ordinary Shares of 0.3p each in Venture Life Group plc

 

 

 

GB00BFPM8908

b)

 

Nature of the transaction

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price

Volume

67.38 pence

2,959

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A - Single transaction

 

 

 

 

 

 

e)

 

Date of the transaction

 

29 January 2026

f)

 

Place of the transaction

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAXAAFDPKEFA
Date   Source Headline
25th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
3rd Oct 20254:40 pmRNSDirector/PDMR Shareholding
30th Sep 20257:01 amRNSShare Buyback Programme
30th Sep 20257:00 amRNSInterim Results
29th Sep 202512:19 pmRNSInvestor Presentation via Investor Meet Company
24th Sep 20252:38 pmRNSChange of Accounting Reference Date
8th Sep 20257:00 amRNSDirectorate Change
19th Aug 20252:04 pmRNSHolding(s) in Company
5th Aug 20253:43 pmRNSResult of General Meeting
25th Jul 20257:05 amRNSGrant of Share Options
25th Jul 20257:00 amRNSCompletion of Divestment & Trading Update
7th Jul 20254:21 pmRNSDirector/PDMR Shareholding
3rd Jul 20257:00 amRNSDirector Dealings
2nd Jul 20257:00 amRNSNotice of General Meeting & Investor Presentation
1st Jul 20254:08 pmRNSHolding(s) in Company
30th Jun 20253:15 pmRNSResult of AGM
30th Jun 20253:13 pmRNSFinal Results for year ended 31 December 2024
5th Jun 20252:19 pmRNSNotice of Annual General Meeting
19th May 20257:01 amRNSDirector Dealings
19th May 20257:00 amRNSBoard Update
12th May 20258:49 amRNSReplacement: Cash sale of CDMO operations
12th May 20257:00 amRNSCash sale of CDMO operations
28th Apr 202510:50 amRNSHolding(s) in Company
8th Apr 20254:53 pmRNSHolding(s) in Company
20th Feb 20251:14 pmRNSHolding(s) in Company
18th Feb 202510:02 amRNSHolding(s) in Company
4th Feb 20257:01 amRNSBoard Changes
4th Feb 20257:00 amRNSTrading Statement
21st Jan 20258:15 amRNSExercise of Share Options & Total Voting Rights
20th Jan 202511:49 amRNSHolding(s) in Company
19th Dec 202411:48 amRNSHolding(s) in Company
4th Nov 20243:44 pmRNSHolding(s) in Company
30th Oct 202412:01 pmRNSDirector/PDMR Shareholding
30th Oct 202410:58 amRNSDirector/PDMR Shareholding
30th Oct 20247:00 amRNSAcquisition of Health & Her Limited
1st Oct 202412:47 pmRNSHolding(s) in Company
30th Sep 20247:00 amRNSInterim Results
26th Sep 20247:00 amRNSInvestor Presentation via Investor Meet Company
2nd Sep 202410:41 amRNSDirector/PDMR Shareholding
2nd Sep 202410:40 amRNSReplacement - Exercise of Options & TVR
23rd Aug 20247:00 amRNSExercise of Options, Director Dealings & TVR
9th Aug 20241:17 pmRNSHolding(s) in Company
6th Aug 20247:00 amRNSTrading Update
25th Jul 20243:54 pmRNSHolding(s) in Company
11th Jul 202410:08 amRNSHolding(s) in Company
19th Jun 20242:46 pmRNSPosting of Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.